| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
1 Professorial Unit of Surgery, North Tees General Hospital, Stockton on Tees, TS19 8PE, UK
2 Department of Surgery, Central Sheffield University Hospitals, Sheffield S10 2JF, UK
3 Department of Histopathology, Central Sheffield University Hospitals, Sheffield, UK
4 Department of Surgical and Anaesthetic Sciences, University of Sheffield, Sheffield, UK
Correspondence: Dr Garbett email: drlizbaker{at}yahoo.co.uk
Background—The process of proteolysis is important at several stages of the metastatic cascade. A balance between the expression of the genes encoding endogenous proteinases and inhibitors exists and when the production of proteinases exceeds that of inhibitors proteolysis occurs.
Aims—To determine whether differences in the profile and activity of proteinases and inhibitors exist within breast tumour tissue (n = 51), surrounding background breast tissue (n = 43), normal breast tissue from breast reduction mammoplasty operations (n = 10), and cells of the breast cancer cell line, MCF-7.
Methods—Proteinase (matrix metalloproteinase 1 (MMP-1), MMP-2, MMP-3, MMP-9, urokinase-type plasminogen activator (uPA), and tissue-type PA (tPA)) and inhibitor (tissue inhibitor of metalloproteinases; TIMP-1 and TIMP-2) expression and proteinase activity were compared using substrate zymography, western blotting, immunohistochemistry, and quenched fluorescent substrate hydrolysis.
Results—The presence of all proteinases and inhibitors was greater in breast tumour tissue when compared with all other types of breast tissue (p < 0.05). The activity of total MMPs as determined by quenched fluorescent substrate hydrolysis was also greater in breast tumours (p < 0.05).
Conclusion—There is increased proteolysis in human breast tumours when compared with other breast tissues.
Key Words: breast cancer • matrix metalloproteinases • metastasis
This article has been cited by other articles:
|
|
 |
|
  Y. Jia, Z.-Z. Zeng, S. M. Markwart, K. F. Rockwood, K. M. W. Ignatoski, S. P. Ethier, and D. L. Livant Integrin Fibronectin Receptors in Matrix Metalloproteinase-1-Dependent Invasion by Breast Cancer and Mammary Epithelial Cells Cancer Res., December 1, 2004; 64(23): 8674 - 8681. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Pellikainen, K. M. Ropponen, V. V. Kataja, J. K. Kellokoski, M. J. Eskelinen, and V.-M. Kosma Expression of Matrix Metalloproteinase (MMP)-2 and MMP-9 in Breast Cancer with a Special Reference to Activator Protein-2, HER2, and Prognosis Clin. Cancer Res., November 15, 2004; 10(22): 7621 - 7628. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-X. Zhang, K. R. Ward, and J. W. Schrader Multiple Aspects of the Phenotype of Mammary Epithelial Cells Transformed by Expression of Activated M-Ras Depend on an Autocrine Mechanism Mediated by Hepatocyte Growth Factor/Scatter Factor Mol. Cancer Res., April 1, 2004; 2(4): 242 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. M. Price, R. H. Gilman, J. Uddin, S. Recavarren, and J. S. Friedland Unopposed Matrix Metalloproteinase-9 Expression in Human Tuberculous Granuloma and the Role of TNF-{alpha}-Dependent Monocyte Networks J. Immunol., November 15, 2003; 171(10): 5579 - 5586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E A Baker, T J Stephenson, M W R Reed, and N J Brown Expression of proteinases and inhibitors in human breast cancer progression and survival Mol. Pathol., October 1, 2002; 55(5): 300 - 304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. C. L. Lin, A. S. Eng, N. E. Hen, E. H. L. Ng, and S. H. Chowdhury Effect of Progesterone on the Invasive Properties and Tumor Growth of Progesterone Receptor-transfected Breast Cancer Cells MDA-MB-231 Clin. Cancer Res., September 1, 2001; 7(9): 2880 - 2886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ylisirnio, M. Hoyhtya, R. Makitaro, P. Paaakko, J. Risteli, V. L. Kinnula, T. Turpeenniemi-Hujanen, and A. Jukkola Elevated Serum Levels of Type I Collagen Degradation Marker ICTP and Tissue Inhibitor of Metalloproteinase (TIMP) 1 Are Associated with Poor Prognosis in Lung Cancer Clin. Cancer Res., June 1, 2001; 7(6): 1633 - 1637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. H. Contag, R. Weissleder, M. H. Bachmann, and S. E. Fraser Applications of In Vivo Molecular Imaging in Biology and Medicine NeoReviews, December 1, 2000; 1(12): e233 - 240. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
| Molecular Pathology | Journal of Clinical Pathology |
